274 related articles for article (PubMed ID: 34664256)
21. Modeling clonal structure over narrow time frames via circulating tumor DNA in metastatic breast cancer.
Weber ZT; Collier KA; Tallman D; Forman J; Shukla S; Asad S; Rhoades J; Freeman S; Parsons HA; Williams NO; Barroso-Sousa R; Stover EH; Mahdi H; Cibulskis C; Lennon NJ; Ha G; Adalsteinsson VA; Tolaney SM; Stover DG
Genome Med; 2021 May; 13(1):89. PubMed ID: 34016182
[TBL] [Abstract][Full Text] [Related]
22. Circulating tumor DNA: clinical roles in diffuse large B cell lymphoma.
Wu FT; Lu L; Xu W; Li JY
Ann Hematol; 2019 Feb; 98(2):255-269. PubMed ID: 30368587
[TBL] [Abstract][Full Text] [Related]
23. c-MYC and p53 expression highlight starry-sky pattern as a favourable prognostic feature in R-CHOP-treated diffuse large B-cell lymphoma.
Bouroumeau A; Bussot L; Bonnefoix T; Fournier C; Chapusot C; Casasnovas O; Martin L; McLeer A; Col E; David-Boudet L; Lefebvre C; Algrin C; Raskovalova T; Jacob MC; Vettier C; Chevalier S; Callanan MB; Gressin R; Emadali A; Sartelet H
J Pathol Clin Res; 2021 Nov; 7(6):604-615. PubMed ID: 34374220
[TBL] [Abstract][Full Text] [Related]
24. Baseline circulating tumour DNA and total metabolic tumour volume as early outcome predictors in aggressive large B-cell lymphoma. A real-world 112-patient cohort.
Le Goff E; Blanc-Durand P; Roulin L; Lafont C; Loyaux R; MBoumbae DL; Benmaad I; Claudel A; Poullot E; Robe C; Gricourt G; Aissat A; Copie-Bergman C; Lemonnier F; Gaulard P; Itti E; Haioun C; Delfau-Larue MH
Br J Haematol; 2023 Jul; 202(1):54-64. PubMed ID: 37038217
[TBL] [Abstract][Full Text] [Related]
25. Detection of ctDNA in plasma of patients with clinically localised prostate cancer is associated with rapid disease progression.
Lau E; McCoy P; Reeves F; Chow K; Clarkson M; Kwan EM; Packwood K; Northen H; He M; Kingsbury Z; Mangiola S; Kerger M; Furrer MA; Crowe H; Costello AJ; McBride DJ; Ross MT; Pope B; Hovens CM; Corcoran NM
Genome Med; 2020 Aug; 12(1):72. PubMed ID: 32807235
[TBL] [Abstract][Full Text] [Related]
26. Identification and monitoring of somatic mutations in circulating cell-free tumor DNA in lung cancer patients.
Francaviglia I; Magliacane G; Lazzari C; Grassini G; Brunetto E; Dal Cin E; Girlando S; Medicina D; Smart CE; Bulotta A; Gregorc V; Pecciarini L; Doglioni C; Cangi MG
Lung Cancer; 2019 Aug; 134():225-232. PubMed ID: 31319985
[TBL] [Abstract][Full Text] [Related]
27. Mutation profiling, tumour burden assessment, outcome prediction and disease monitoring by circulating tumour DNA in peripheral T-cell lymphoma.
Wei C; Wang W; Zhang Y; Zhao D; Zhang W; Zhou D
Br J Haematol; 2023 Jul; 202(1):86-95. PubMed ID: 37132364
[TBL] [Abstract][Full Text] [Related]
28. Mutational profiling of circulating tumor DNA and clinical characteristics in lymphoma: Based on next generation sequencing.
Hou Y; Zi J; Liu S; Ge Q; Ge Z
Mol Carcinog; 2023 Feb; 62(2):200-209. PubMed ID: 36300887
[TBL] [Abstract][Full Text] [Related]
29. Clinical aspects of TP53 gene inactivation in diffuse large B-cell lymphoma.
Voropaeva EN; Pospelova TI; Voevoda MI; Maksimov VN; Orlov YL; Seregina OB
BMC Med Genomics; 2019 Mar; 12(Suppl 2):35. PubMed ID: 30871527
[TBL] [Abstract][Full Text] [Related]
30. Longitudinal profiling of circulating tumour DNA for tracking tumour dynamics in pancreatic cancer.
Sivapalan L; Thorn GJ; Gadaleta E; Kocher HM; Ross-Adams H; Chelala C
BMC Cancer; 2022 Apr; 22(1):369. PubMed ID: 35392854
[TBL] [Abstract][Full Text] [Related]
31. Circulating tumour DNA and CT monitoring in patients with untreated diffuse large B-cell lymphoma: a correlative biomarker study.
Roschewski M; Dunleavy K; Pittaluga S; Moorhead M; Pepin F; Kong K; Shovlin M; Jaffe ES; Staudt LM; Lai C; Steinberg SM; Chen CC; Zheng J; Willis TD; Faham M; Wilson WH
Lancet Oncol; 2015 May; 16(5):541-9. PubMed ID: 25842160
[TBL] [Abstract][Full Text] [Related]
32. Non-invasive monitoring of diffuse large B-cell lymphoma by cell-free DNA high-throughput targeted sequencing: analysis of a prospective cohort.
Bohers E; Viailly PJ; Becker S; Marchand V; Ruminy P; Maingonnat C; Bertrand P; Etancelin P; Picquenot JM; Camus V; Menard AL; Lemasle E; Contentin N; Leprêtre S; Lenain P; Stamatoullas A; Lanic H; Libraire J; Vaudaux S; Pepin LF; Vera P; Tilly H; Jardin F
Blood Cancer J; 2018 Aug; 8(8):74. PubMed ID: 30069017
[TBL] [Abstract][Full Text] [Related]
33. Circulating tumor DNA mutation profile is associated with the prognosis and treatment response of Chinese patients with newly diagnosed diffuse large B-cell lymphoma.
Guan T; Zhang M; Liu X; Li J; Xin B; Ren Y; Yang Y; Wang H; Zhao M; Huang Y; Guo X; Du J; Qian W; Su L
Front Oncol; 2022; 12():1003957. PubMed ID: 36465410
[TBL] [Abstract][Full Text] [Related]
34. [Clinical Application of Circulating Tumor DNA in Diffuse Large B-Cell Lymphoma--Review].
Chen XF; Wang M; Zhang F; Li JJ
Zhongguo Shi Yan Xue Ye Xue Za Zhi; 2021 Apr; 29(2):638-642. PubMed ID: 33812444
[TBL] [Abstract][Full Text] [Related]
35. Mutations or copy number losses of CD58 and TP53 genes in diffuse large B cell lymphoma are independent unfavorable prognostic factors.
Cao Y; Zhu T; Zhang P; Xiao M; Yi S; Yang Y; Li Q; Ling S; Wang Y; Gao L; Zhu L; Wang J; Wang N; Huang L; Zhang P; Zhai Q; Qiu L; Zhou J
Oncotarget; 2016 Dec; 7(50):83294-83307. PubMed ID: 27825110
[TBL] [Abstract][Full Text] [Related]
36. Circulating Tumor DNA-Based Genotyping and Monitoring for Predicting Disease Relapses of Patients with Peripheral T-Cell Lymphomas.
Kim SJ; Kim YJ; Yoon SE; Ryu KJ; Park B; Park D; Cho D; Kim HY; Cho J; Ko YH; Park WY; Kim WS
Cancer Res Treat; 2023 Jan; 55(1):291-303. PubMed ID: 35240014
[TBL] [Abstract][Full Text] [Related]
37. Promoter hypermethylation of the DNA-repair gene O6-methylguanine-DNA methyltransferase and p53 mutation in diffuse large B-cell lymphoma.
Hiraga J; Kinoshita T; Ohno T; Mori N; Ohashi H; Fukami S; Noda A; Ichikawa A; Naoe T
Int J Hematol; 2006 Oct; 84(3):248-55. PubMed ID: 17050200
[TBL] [Abstract][Full Text] [Related]
38. Retrospective analyses of other iatrogenic immunodeficiency-associated lymphoproliferative disorders in patients with rheumatic diseases.
Kaji D; Kusakabe M; Sakata-Yanagimoto M; Makishima K; Suehara Y; Hattori K; Ota Y; Mitsuki T; Yuasa M; Kageyama K; Taya Y; Nishida A; Ishiwata K; Takagi S; Yamamoto H; Asano-Mori Y; Ubara Y; Izutsu K; Uchida N; Wake A; Taniguchi S; Yamamoto G; Chiba S
Br J Haematol; 2021 Nov; 195(4):585-594. PubMed ID: 34558064
[TBL] [Abstract][Full Text] [Related]
39. Mutational profile and prognostic significance of TP53 in diffuse large B-cell lymphoma patients treated with R-CHOP: report from an International DLBCL Rituximab-CHOP Consortium Program Study.
Xu-Monette ZY; Wu L; Visco C; Tai YC; Tzankov A; Liu WM; Montes-Moreno S; Dybkaer K; Chiu A; Orazi A; Zu Y; Bhagat G; Richards KL; Hsi ED; Zhao XF; Choi WW; Zhao X; van Krieken JH; Huang Q; Huh J; Ai W; Ponzoni M; Ferreri AJ; Zhou F; Kahl BS; Winter JN; Xu W; Li J; Go RS; Li Y; Piris MA; Møller MB; Miranda RN; Abruzzo LV; Medeiros LJ; Young KH
Blood; 2012 Nov; 120(19):3986-96. PubMed ID: 22955915
[TBL] [Abstract][Full Text] [Related]
40. Monitoring treatment efficacy and resistance in breast cancer patients via circulating tumor DNA genomic profiling.
Chen Z; Sun T; Yang Z; Zheng Y; Yu R; Wu X; Yan J; Shao YW; Shao X; Cao W; Wang X
Mol Genet Genomic Med; 2020 Feb; 8(2):e1079. PubMed ID: 31867841
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
